Plasmacytoma variant translocation 1 (PVT1), an interacting partner of tumor suppressor and pro-apoptotic gene silencing in multiple myeloma, was overexpressed in patients with poor prognosis, and inhibition of the PVT1 expression was found to promote the expression of RNF144A, which may be a new research direction in multiple myeloma [46]. This evidence concerns the gene PVT1 and plasma cell myeloma.